These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23488108)

  • 21. Medicaid reimbursement. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-13. PubMed ID: 19297676
    [No Abstract]   [Full Text] [Related]  

  • 22. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Need for integrated data in pharmacy benefits.
    Martens G; Clor GE
    J Health Care Benefits; 1993; 3(1):57-60. PubMed ID: 10130352
    [No Abstract]   [Full Text] [Related]  

  • 24. The many different prices paid to providers and the flawed theory of cost shifting: is it time for a more rational all-payer system?
    Reinhardt UE
    Health Aff (Millwood); 2011 Nov; 30(11):2125-33. PubMed ID: 22068405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicare overpaid dollar 110 million for part B drugs.
    Med Health; 2006 Mar; 60(13):2-3. PubMed ID: 16562555
    [No Abstract]   [Full Text] [Related]  

  • 26. Controlling the cost of branded drugs.
    Mandelker J
    Bus Health; 1993 Nov; 11(13):44-6, 48. PubMed ID: 10130506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 28. Charges billed to third parties for prescription drugs furnished by VA to a veteran for a nonservice-connected disability. Final rule.
    Department of Veterans Affairs
    Fed Regist; 2010 Oct; 75(193):61621-3. PubMed ID: 20931727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. If foreign drug prices go up, will U.S. prices come down?
    Med Health; 2003 Dec; 57(45):2-4. PubMed ID: 14723168
    [No Abstract]   [Full Text] [Related]  

  • 30. Do drug copayments work?
    David J
    CMAJ; 1994 May; 150(9):1491-3. PubMed ID: 8168015
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular medicine, the Medicare drug benefit, and the need for cost control.
    Gillick MR
    J Am Geriatr Soc; 2006 Sep; 54(9):1442-6. PubMed ID: 16970656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plans confront specialty pharmacy's escalating costs in variety of ways.
    Reinke T
    Manag Care; 2010 Dec; 19(12):12-3, 15-6, 19. PubMed ID: 21291126
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs of severely ill members and specialty medication use in a commercially insured population.
    Willey VJ; Pollack MF; Lednar WM; Yang WN; Kennedy C; Lawless G
    Health Aff (Millwood); 2008; 27(3):824-34. PubMed ID: 18474976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New federal guidelines: a green light from government.
    Gosselin RA
    Hosp Formul; 1978 Jul; 13(7):546-9. PubMed ID: 10308293
    [No Abstract]   [Full Text] [Related]  

  • 38. Prescription drug benefits: Rx for cost management--commentary.
    Carlsen MA
    Benefits Q; 1993; 9(3):81-8. PubMed ID: 10127207
    [No Abstract]   [Full Text] [Related]  

  • 39. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlling pharmacy costs in the NC Medicaid program.
    Dobson LA
    N C Med J; 2003; 64(6):280-2. PubMed ID: 14983617
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.